Skip to main content
University of California San Francisco
UCSF  |  
About UCSF   |   Search UCSF
Home
Technology Disclosure
  • Services
    • HealthTech Commercialization
    • Innovation & Entrepreneurship
    • Funding for Translational Technology
  • Teams
    • Engagement & Opportunity Development
    • Technology Licensing
    • Strategic Alliances
    • Business Affairs & Strategic Partnerships
    • Catalyst
  • Resources
    • Policies
    • Forms
    • Outgoing Material Transfer
    • Industry Statistics
    • Startup Resources
    • Translational Opportunities
    • Jobs & Internships
    • Partnering with Industry FAQs
    • Protecting Your Idea
    • Technology Disclosure
  • About
    • Events
    • Contact
    • Success Stories
    • Featured Startups
    • Teams
  • Media
    • News
    • Newsletters
    • Podcasts
    • Videos
  • linkedin
  • vimeo
  • youtube
Skip to main content
  • Home
  • Media
  • News

Aer Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Fexlamose in Chronic Obstructive Pulmonary Disease

  January 9, 2025
  •  Share this:
  • Share on Facebook
  • Share on Reddit
  • Copy link
  • Email
  • Print
  • About
    • Events
    • Contact
    • Featured Startups
    • Success Stories
    • Teams
  • Teams
    • Engagement & Opportunity Development
    • Technology Licensing
    • Strategic Alliances
    • Business Affairs & Strategic Partnerships
    • Catalyst
  • Services
    • HealthTech Commercialization
    • Innovation & Entrepreneurship
    • Funding
    • Catalyst Program
  • Partnerships
    • Finding an Industry Partner
    • Establishing Research Collaborations
    • Panther Program
    • Precision Medicine
    • QB3
    • UCSF Health
  • Resources
    • Innovation Showcase
    • Translational Opportunities
    • Forms
    • Outgoing Material Transfer
    • Policies
    • Startup Resources
    • Partnering with Industry FAQs
    • Leadership Dashboard
    • Protecting Your Idea
    • Technology Disclosure

RECENT NEWS

  • UCSF Receives $824M in NIH Funding, Driving Medical Breakthroughs
  • Molecular Garbage on Tumors Makes Easy Target for Antibody Drugs
  • VS3 Medical Announces First Patients Enrolled in First-in-Human Study of Novel Neurovascular Implant to Address Symptomatic Venous Sinus Stenosis

Contact

  • Email:  [email protected]
  • UCSF Wayne and Gladys Valley Center
    490 Illinois Street, North Tower, 400-A
    San Francisco, CA 94143
  • Campus Mail: PO box: 2142
  • linkedin
  • vimeo
  • youtube
2026 ©  The Regents of the University of California
  • Accessibility
  • Usage
  • Privacy